DK1649023T3 - Polypeptide with enhanced cytosine deaminase activity - Google Patents

Polypeptide with enhanced cytosine deaminase activity

Info

Publication number
DK1649023T3
DK1649023T3 DK04744156T DK04744156T DK1649023T3 DK 1649023 T3 DK1649023 T3 DK 1649023T3 DK 04744156 T DK04744156 T DK 04744156T DK 04744156 T DK04744156 T DK 04744156T DK 1649023 T3 DK1649023 T3 DK 1649023T3
Authority
DK
Denmark
Prior art keywords
polypeptide
enhanced
cytosine deaminase
deaminase activity
activity
Prior art date
Application number
DK04744156T
Other languages
Danish (da)
Inventor
Philippe Erbs
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of DK1649023T3 publication Critical patent/DK1649023T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a polypeptide possessing a CDase activity, characterized in that it is derived from a native CDase by addition of an amino acid sequence with the proviso that said polypeptide has no UPRtase or Thymidine Kinase activity.
DK04744156T 2003-07-21 2004-06-29 Polypeptide with enhanced cytosine deaminase activity DK1649023T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03360087 2003-07-21
US50827403P 2003-10-06 2003-10-06
PCT/IB2004/002505 WO2005007857A1 (en) 2003-07-21 2004-06-29 Polypeptide having an improved cytosine deaminase activity

Publications (1)

Publication Number Publication Date
DK1649023T3 true DK1649023T3 (en) 2008-10-06

Family

ID=39719832

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04744156T DK1649023T3 (en) 2003-07-21 2004-06-29 Polypeptide with enhanced cytosine deaminase activity

Country Status (17)

Country Link
US (3) US7790445B2 (en)
EP (2) EP1897938B9 (en)
JP (1) JP4672659B2 (en)
KR (1) KR101062140B1 (en)
CN (1) CN1826410B (en)
AT (1) ATE405654T1 (en)
AU (1) AU2004257935B2 (en)
CA (1) CA2532783C (en)
CY (1) CY1110397T1 (en)
DE (1) DE602004015995D1 (en)
DK (1) DK1649023T3 (en)
ES (1) ES2311831T3 (en)
HK (2) HK1112024A1 (en)
IL (1) IL173158A (en)
PL (1) PL1649023T3 (en)
PT (1) PT1649023E (en)
WO (1) WO2005007857A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2551982C2 (en) 2006-06-20 2015-06-10 Трансжене С.А. Method of obtaining poxviruses and compositions of poxviruses
CA2691868C (en) 2007-07-03 2016-12-20 Transgene S.A. Immortalized avian cell lines
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
ES2706899T3 (en) * 2008-09-26 2019-04-01 Tocagen Inc Vectors of gene therapy and cytosine deaminase
CN102740881A (en) 2009-05-12 2012-10-17 特兰斯吉恩股份有限公司 Method for orthopoxvirus production and purification
TW201109440A (en) 2009-07-21 2011-03-16 Transgene Sa Enzymatic composition for the digestion of chicken embryos
EP2527432A1 (en) * 2011-05-23 2012-11-28 Novozymes A/S Bi-directional cytosine deaminase-encoding selection marker
WO2013004658A1 (en) 2011-07-01 2013-01-10 Transgene Sa Formulations of 5-fluorocytosine and uses thereof.
US9642921B2 (en) 2012-12-20 2017-05-09 Tocagen Inc. Cancer combination therapy and recombinant vectors
CN106413726B (en) 2014-04-10 2020-07-24 特朗斯吉有限公司 Poxvirus oncolytic vectors
CA3190510A1 (en) 2014-07-16 2016-01-21 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
WO2016087457A1 (en) 2014-12-01 2016-06-09 Transgene Sa Stable liquid vaccinia virus formulations
CN107949397A (en) * 2015-02-13 2018-04-20 特兰斯吉恩股份有限公司 Immunization therapy vaccine and Antibody Combination treatment
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
US10888594B2 (en) * 2016-05-30 2021-01-12 National University Corporation Tottori University Genetically engineered vaccinia viruses
US20190336552A1 (en) 2016-05-30 2019-11-07 Astellas Pharma Inc. Genetically engineered vaccinia viruses
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa Oncolytic viruses expressing agents targeting metabolic immune modulators
EP3762020A1 (en) 2018-03-07 2021-01-13 Transgene Parapoxvirus vectors
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
JP7484717B2 (en) 2018-09-26 2024-05-16 アステラス製薬株式会社 Cancer therapy using a combination of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination drug for use therein
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
TW202413636A (en) 2022-08-18 2024-04-01 法商傳斯堅公司 Chimeric poxviruses

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
FR2583429B1 (en) 1985-06-18 1989-11-03 Transgene Sa INTERFERON U EXPRESSION VECTOR IN MAMMALIAN CELLS, PROCESS FOR IMPLEMENTING SAME AND PRODUCT OBTAINED, AND PHARMACEUTICAL COMPOSITION CONTAINING INTERFERON U
CA2018273C (en) * 1989-06-09 1999-04-06 Peter D. Senter Thermally stable cytosine deaminase
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
PT931830E (en) 1993-02-16 2001-08-30 Onyx Pharma Inc CITOPATHIC VIRUSES FOR NEOPLASY THERAPY AND PROFILAXIA
WO1994028143A1 (en) * 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
FR2705686B1 (en) 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
FR2722208B1 (en) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med NEW INTERNAL RIBOSOME ENTRY SITE, VECTOR CONTAINING SAME AND THERAPEUTIC USE
US5856153A (en) 1994-11-17 1999-01-05 Cayla Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases
FR2727689A1 (en) 1994-12-01 1996-06-07 Transgene Sa NEW PROCESS FOR THE PREPARATION OF A VIRAL VECTOR
FR2737222B1 (en) 1995-07-24 1997-10-17 Transgene Sa NEW VIRAL AND LINEAR VECTORS FOR GENE THERAPY
FR2759382A1 (en) 1997-02-10 1998-08-14 Transgene Sa NOVEL COMPOUNDS AND COMPOSITIONS CONTAINING THEM FOR USE IN TRANSFERRING AT LEAST ONE THERAPEUTICALLY ACTIVE SUBSTANCE, IN PARTICULAR A POLYNUCLEOTIDE, INTO A TARGET CELL AND USE IN GENE THERAPY
FR2762615B1 (en) 1997-04-28 1999-07-16 Inst Nat Sante Rech Med NEW INTERNAL RIBOSOME ENTRY SITE AND VECTOR CONTAINING THE SAME
FR2777570A1 (en) 1998-04-17 1999-10-22 Transgene Sa Novel mutant enzyme and related fusion proteins, useful for gene therapy of cancer, by prodrug activation
US6552005B1 (en) * 1998-09-29 2003-04-22 Uab Research Foundation Molecular chemotherapy enhancement of radiotherapy
US20030121068A1 (en) * 2001-11-30 2003-06-26 Paul Orchard Vector encoding suicide and marker constructs
US7141404B2 (en) * 2002-12-27 2006-11-28 Onyx Pharmaceuticals, Inc. Candida kefyr cytosine deaminase

Also Published As

Publication number Publication date
US20100330031A1 (en) 2010-12-30
CN1826410A (en) 2006-08-30
HK1084150A1 (en) 2006-07-21
US8257692B2 (en) 2012-09-04
IL173158A (en) 2009-12-24
EP1649023B1 (en) 2008-08-20
EP1897938B9 (en) 2011-08-31
PT1649023E (en) 2008-11-20
US8226954B2 (en) 2012-07-24
ATE405654T1 (en) 2008-09-15
DE602004015995D1 (en) 2008-10-02
US7790445B2 (en) 2010-09-07
US20100330051A1 (en) 2010-12-30
EP1897938A1 (en) 2008-03-12
EP1649023A1 (en) 2006-04-26
CA2532783C (en) 2013-09-17
EP1897938B1 (en) 2010-10-06
KR20060040697A (en) 2006-05-10
WO2005007857A1 (en) 2005-01-27
PL1649023T3 (en) 2009-01-30
HK1112024A1 (en) 2008-08-22
CA2532783A1 (en) 2005-01-27
IL173158A0 (en) 2006-06-11
AU2004257935B2 (en) 2009-11-19
CY1110397T1 (en) 2015-04-29
CN1826410B (en) 2011-10-26
KR101062140B1 (en) 2011-09-05
JP2006527994A (en) 2006-12-14
ES2311831T3 (en) 2009-02-16
JP4672659B2 (en) 2011-04-20
AU2004257935A1 (en) 2005-01-27
US20070264235A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
HK1112024A1 (en) Polypeptide having an improved cytosine deaminase activity
ATE417595T1 (en) KERATIN-BINDING POLYPEPTIDES
BRPI0517493A (en) isolated polynucleotide, expression vector promoter, host cell and use of a polynucleotide
CY1110028T1 (en) Polypeptides for the Production of Protective Immunosuppressants Against STAPHYLOCOCCUS AUREUS
EA201200398A1 (en) POLYPEPTIDES WITH OXIDOCUTAZA ACTIVITY AND THEIR APPLICATION
DK1454138T3 (en) Immunocytokines with modulated selectivity
ATE435923T1 (en) NEW POLYNUCLEOTIDES AND POLYPEPTIDES OF ERYTHROPOIETINE
DK1423419T3 (en) Hybrid and tandem expression of Neisseria proteins
ATE462000T1 (en) METHOD FOR PRODUCING L-ARGININE, L-ORNITHINE OR L-CITRULLINE
ATE497975T1 (en) IL-21 VARIANTS
RS51325B (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
DE60335549D1 (en) Recovery of heat shock proteins
DK1778271T3 (en) Peptide for the treatment of herpes virus infections
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
ATE414156T1 (en) LIPASE VARIANTS
DE602005025989D1 (en) OF 2 ', 3'-DIDESOXYNUCLEOSIDES AND 2', 3'-DIDEHYDRO-2 ', 3'-DIDESOXYNUCLEOSIDES
NO20051938L (en) Promoter for IL-18BP, its preparation and use
NO20082864L (en) New polypeptide with esterase activity and recombinant esterase and its use
FR2902101B1 (en) PEPTIDES WITH ANTI-PROLIFERATIVE ACTIVITY
WO2003072733A3 (en) Modified bace
TW200617021A (en) Isolated photoprotein aequorin y89f, and its use
ATE387494T1 (en) HEAT-LASABLE DESOXYRIBONUCLEASE I VARIANTS
GB2441941A (en) An isolated recombinant vaccinia virus complement control protein (HRVCP) polypeptide
WO2006122650A3 (en) Isolated aqdecay photoprotein and use thereof
TW200716666A (en) Isolated photoprotein gr-bolinopsin, and its use